DecisionDx-UM
Commercial- Indications
- Uveal melanoma
Company intelligence / Profile preview
Castle Biosciences has demonstrated strong clinical utility across its portfolio, with more than 150 peer-reviewed publications supporting its tests. Over 300,000 test reports have been delivered since inception. In recent years, the company has shown significant revenue growth and increasing adoption among clinicians. Its pipeline includes a precision medicine test for atopic dermatitis currently in validation studies.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Castle Biosciences.